Top

Journal of Neurology

Published in:

Open Access 01-05-2020 | Botulinum Toxin | Original Communication

Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study

Authors: Harald Hefter, Raphaela Brauns, Beyza Ürer, Dietmar Rosenthal, Philipp Albrecht

Published in: Journal of Neurology | Issue 5/2020

Abstract

Background

Among the spectrum of licensed botulinum neurotoxin preparations incobotulinumtoxin (incoBoNT/A; Xeomin®) is the only one which does not contain complex proteins. Therefore, incoBoNT/A has been suggested to have a low antigenicity, but precise estimations on incidence and prevalence of neutralizing antibody formation during long-term treatment are outstanding so far.

Methods

For the present cross-sectional study, 59 patients having exclusively been treated with incoBoNT/A (mono group) and 32 patients having been treated with other BoNT/A preparations less than nine times and who were then switched to at least 14 sessions of incoBoNT/A treatment (switch group) were recruited from one botulinum toxin outpatient clinic. Side effects and doses were extracted from the charts, and the efficacy of treatment was assessed by the patients using a visual analogue scale (0–100). The prevalence of neutralizing antibodies was tested by means of the mouse hemi-diaphragm assay (MHDA).

Findings

None of the patients in the mono and only two in the switch group had a positive MHDA-test. Across all indications and patients, mean improvement exceeded 67%. Improvement did not depend on age at onset, sex, change of dose or duration of treatment, but on disease entity. In patients with cervical dystonia, improvement was about the same in the mono and switch subgroup, but the last dose was different.

Conclusions

The present study confirms the low antigenicity of incoBoNT/A, which has immediate consequences for patient management, and the use of higher doses and shorter durations of reinjection intervals in botulinum toxin therapy.

Frevert J (2015) Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D 15:1–9CrossRef

Romanov A, Pokushalov E, Ponomarev D et al (2009) Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery: three-year follow-up of a randomized study. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2018.08.019 CrossRefPubMed

International Society of Aesthetic Plastic Surgeons (2014) ISAPS international survey on aesthetic/cosmetic procedures performed in 2013. https://www.isaps.org/news/isaps-global-statistics

Simpson DM, Hallett M, Ashman EJ et al (2016) Practise guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86:1818–1826CrossRef

Van Kooyk Y (2008) C-type lectins on dentritic cells: key modulators for the induction of immune responses. Biochem Soc Trans 36:1478–1481CrossRef

Schulte-Baukloh H, Bigalke H, Miller K, Heine G, Pape D, Lehman J, Knispel HH (2008) Botulinum toxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 15:407–415CrossRef

Berweck S, Schroeder AS, Lee S-H, Bigalke H, Heinen F (2007) Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands. Dev Med Child Neurol 49:62–64CrossRef

Hefter H, Spiess C, Rosenthal D (2014) Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. J Neural Trans (Vienna) 121:513–519CrossRef

Frevert J (2010) Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Boouture®. Drugs R D 10:67–73CrossRef

10.

Gu S, Rumpel S, Zhou J et al (2012) Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335:977–981CrossRef

11.

Lee K, Zhong X, Gu S et al (2014) Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex. Science 344:1405–1410CrossRef

12.

Frevert J, Dressler D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 4:325–332PubMedPubMedCentral

13.

Eisele KH, Fink K, Vey M, Taylor HV (2011) Studies on dissociation of botulinum neurotoxin type A complexes. Toxicon 57:555–565CrossRef

14.

Brown M, Nicholson G, Ardila MC et al (2013) Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations. J Neural Trans 120:291–298CrossRef

15.

Sharma SK, Singh BR (2000) Immunological properties of Hn-33 purified from type A Clostridium botulinum. J Natl Toxins 9:357–362

16.

Bryant AM, Cai S, Singh BR (2013) Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins. Toxicon 72:126–132CrossRef

17.

Blümel J, Frevert J, Schwaier A (2006) Comparative antigenicity of three preparations on botulinum neurotoxin A in the rabbit. Neurotox Res 9:238

18.

Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9:213–217CrossRef

19.

Aoki KR, Merlino G, Spanoyannis AF, Wheeler LA (1999) BOTOX (botulinum toxin type A) purified neurotoxin complex prepared from the bulk toxin retains the same preclinical efficacy as the original but with reduced antigenicity. Neurology 52(Suppl 2):A521–A522

20.

Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60:1186–1188CrossRef

21.

Aoki KR, Guyer B (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 8(Suppl. 5):21–29CrossRef

22.

Hefter H, Rosenthal D, Moll M (2016) High Botulinum Toxin-neutralizing antibody prevalence under long-term cervical dystonia treatment. Mov Disord Clin Pract. https://doi.org/10.1002/mdc3.12322 CrossRefPubMedPubMedCentral

23.

Albrecht P, Jansen A, Lee J-I et al (2018) High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. https://doi.org/10.1212/WNL.0000000000006688 CrossRef

24.

Hefter H, Hartmann C, Kahlen U, Moll M, Bigalke H (2012) Prospective analysis of neutralizing antibody titres in secondary non-responders under continuous treatment with a botulinum toxin type a preparation free of complexing proteins—a single cohort 4-year follow-up study. BMJ Open. https://doi.org/10.1136/bmjopen-2011-000646 CrossRefPubMedPubMedCentral

25.

Goeschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies–therapeutic consequences. Exp Neurol 147:96–102CrossRef

26.

Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2:245–247CrossRef

27.

Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949–1951CrossRef

28.

Moll M, Rosenthal D, Hefter H (2018) Quality of life in long-term botulinum toxin treatment of cervical dystonia: results of a cross sectional study. Park Rel Disord 57:63–67CrossRef

29.

Mejia NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20:592–597CrossRef

30.

Kamm C, Schümann F, Mix E, Benecke A (2015) Letter to the Editor. Secondary antibody-induced treatment failure under therapy with incobotulinumtoxinA (Xeomin®) in a patient with segmental dystonia pretreated with abobotulinumtoxinA (Dysport®). J Neurol Sci 350:110–111CrossRef

31.

Brin MF, Comella CL, Jankovic J et al (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353–1360CrossRef

Title: Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study
Authors: Harald Hefter
Raphaela Brauns
Beyza Ürer
Dietmar Rosenthal
Philipp Albrecht
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keyword: Botulinum Toxin
Published in: Journal of Neurology / Issue 5/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09681-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study

Abstract

Background

Methods

Findings

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Findings

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2020

Microalbuminuria: a sentinel of neurocognitive impairment in HIV-infected individuals?

A pooled meta-analysis of GPi and STN deep brain stimulation outcomes for cervical dystonia

Reversal of spontaneous nystagmus during visual fixation in dorsal medullary infarction

Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort

Pre-treatment cerebral microbleeds and intracranial hemorrhage in patients with ischemic stroke receiving endovascular therapy: a systematic review and meta-analysis

Microbleeds in dementia with Lewy bodies